Labcorp’s Post

Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, making it the most common type of lung cancer. Key subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Interestingly, NSCLC is highly associated with specific genetic mutations like EGFR and ALK, opening the door to precision therapies that can target these changes. Early diagnosis and targeted treatments can greatly improve outcomes. Stay informed on the latest advancements. Follow LARVOL for updates on clinical trials, treatments, and oncology conferences. #NSCLC #LungCancer #Oncology #ClinicalTrials #LARVOL #WCLC2024 #ESMO2024

Advancing Cancer Therapy with Biomarkers! The integration of cancer biomarkers into treatment plans is revolutionizing oncology. By targeting specific molecular features like HER2 in breast cancer and ALK in lung cancer, we're seeing remarkable improvements in patient outcomes. Biomarkers ensure treatments are precise, effective, and personalized. Join us in the fight against cancer with cutting-edge, biomarker-driven therapies! #Oncology #CancerBiomarkers #PersonalizedTreatment #MedicalAdvances #HopeForPatients https://lnkd.in/dFAjZRmM

ANGLE showcases its advances in cancer diagnostics @parsortix #AIM #OTCQX #AGL #ANPCY. ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of a unique liquid biopsy innovation, presented new data at the American Association for Cancer Research Special Conference highlighting significant advances in cancer diagnostics. The company showcased two Parsortix-based assays aimed at improving personalised treatment for patients with lung and breast cancer. The first study introduced an immunofluorescence assay to monitor programmed death ligand-1 (PD-L1) status in circulating tumour cells (CTCs) from metastatic lung cancer patients. PD-L1 is a protein that helps cancer... http://ow.ly/J7Ve105OXmC

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: https://lnkd.in/gEyecuir #Oncology #Immunotherapy #Biomarkers

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: https://lnkd.in/e9BDyUVz #Oncology #Immunotherapy #Biomarkers

🌟 Exploring Evolving Strategies for HR-Positive Breast Cancer with Dr. Virginia Kaklamani 🩺 In a recent interview, Dr. Virginia Kaklamani discussed the rapidly advancing landscape of hormone receptor-positive breast cancer treatments. With the emergence of novel medications like CDK4-6 inhibitors, oral SERDs, and PI3K/AKT pathway inhibitors, she emphasized the need for NGS testing to guide treatment decisions. Dr. Kaklamani highlighted the unique efficacy and safety profiles of alpelisib, inovolacib, and capivacertib, and provided insights on selecting the most suitable therapy based on specific genetic mutations. Learn more about her expert perspectives on optimizing patient outcomes in metastatic breast cancer! 💡 #BreastCancer #Oncology #HRPositive #EndocrineResistance #CancerResearch #OncologyFrontier

Check out this wonderful episode by Drs. Eric Severson and Sarabjot Pabla on how not to *lag* behind T cell exhaustion- targeting LAG-3 may invigorate T cells to attack the cancer cells 🧯🦠 #ImmunoOncology #LAG3 #ImmuneCheckpoint

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: http://spr.ly/6049gBQGD #Oncology #Immunotherapy #Biomarkers

AACR Project GENIE®, a publicly accessible cancer registry of real-world clinico-genomic data, has released its 16th public dataset. The registry now contains more than 214,000 genomic samples from almost 185,000 patients. The combined data set now features 112 major cancer types, including data from approximately 27,000 patients with lung cancer, 18,500 patients with colorectal cancer, and 16,500 patients with breast cancer. Learn more: https://bit.ly/3WkJf4X #AACRGENIE

Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview. Learn how LAG-3 helps tumors evade the immune system and why inhibiting it may enhance existing immunotherapies: https://lnkd.in/gQEGqzrm #Oncology #Immunotherapy #Biomarkers